1. Study protocol for an efficacy trial of the “PrEP for Health” intervention to increase HIV PrEP use among people who inject drugs
- Author
-
Bazzi, Angela R, Bordeu, Michelle, Baumgartner, Katrina, Sproesser, Darien M, Bositis, Christopher M, Krakower, Douglas S, Mimiaga, Matthew J, and Biello, Katie B
- Subjects
Public Health ,Health Sciences ,HIV/AIDS ,Clinical Trials and Supportive Activities ,Substance Misuse ,Sexual and Gender Minorities (SGM/LGBT*) ,Drug Abuse (NIDA only) ,Clinical Research ,Behavioral and Social Science ,Prevention ,Infectious Diseases ,Prevention of disease and conditions ,and promotion of well-being ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Infection ,Good Health and Well Being ,Female ,Humans ,United States ,HIV Infections ,Substance Abuse ,Intravenous ,Drug Users ,Anti-Retroviral Agents ,Sexual Behavior ,Pre-Exposure Prophylaxis ,Anti-HIV Agents ,Randomized Controlled Trials as Topic ,HIV infections ,Opioid-related Disorders ,Substance-related Disorders ,Needle-Exchange Programs ,Substance Use ,Intravenous ,Motivational interviewing ,Self Efficacy ,Patient Navigation ,Social Cognitive Theory ,Substance Use ,Intravenous ,Public Health and Health Services ,Epidemiology ,Health services and systems ,Public health - Abstract
BackgroundHIV incidence has recently increased among people who inject drugs (PWID) across the United States, with outbreaks occurring in states with long-standing syringe service programs (SSPs) including Massachusetts (MA). Antiretroviral pre-exposure prophylaxis (PrEP) is an evidence-based HIV prevention strategy recommended for PWID, but uptake in this marginalized population is extraordinarily low.MethodsWe describe the design and procedures for a National Institute on Drug Abuse (NIDA)-funded (R01) randomized controlled trial (RCT) testing the efficacy of "PrEP for Health," a multicomponent behavioral intervention to increase PrEP uptake, adherence, and persistence among HIV-negative PWID attending SSPs in two areas of the U.S. Northeast that are heavily affected by injection-related HIV transmission. Participants are equally randomized to receive the "PrEP for Health" intervention (involving individually tailored HIV and PrEP education, motivational interviewing, problem-solving skills and planning, and ongoing navigation support) or an enhanced standard of care (eSOC) control condition involving a brief educational video on the utility of PrEP for HIV prevention. Co-primary outcomes are PrEP uptake (using medical/pharmacy records) and adherence (using tenofovir quantification in hair samples); a secondary outcome is PrEP persistence (using medical/pharmacy records) over 12 months. Major assessments occur at baseline, 1-, 3-, 6-, and 12-month follow-up visits. Planned analyses will examine intervention efficacy, specific hypothesized conceptual mediators of the intervention effect (e.g., self-perceived HIV risk; PrEP knowledge, interest in use, motivation, and behavioral skills) and epidemiologically linked moderators (e.g., age; gender; condomless vaginal or anal sex).DiscussionFindings from our extensive preliminary research with the study population revealed that a multicomponent, theory-based intervention targeting PrEP knowledge, motivation, self-efficacy, behavioral skills, and structural barriers to PrEP access is urgently needed for PWID who are at risk of HIV acquisition. We also learned that SSPs represent a highly acceptable service setting for delivering such interventions. In this study, we are evaluating the efficacy of the "PrEP for Health" intervention. If efficacious, findings from our implementation evaluation could help guide its dissemination to diverse SSPs and possibly other community-based settings accessed by this population.Trial registrationClinicalTrials.gov number NCT04430257, registered June 12, 2020.
- Published
- 2023